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INTRODUCTION
Vasoactive intestinal peptide-secreting tumor
(VIPoma) is an extremely rare tumors that cause
the watery diarrhea, hypokalemia, and acidosis
syndrome (WDHHA syndrome). In 1958, Verner and
Morrison first described refractory watery diarrhea and
hypokalemia associated with non-insulin-secreting
pancreatic islets tumor. The absence of gastric hyper-
secretion and even achlorhydria were documented in
patients with this tumor syndrome later termed
pancreatic cholera.1,2 The appropriate acronym should
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ABSTRACT
Vasoactive intestinal peptide-secreting tumor (VIPoma) is one of the tumors which cause “watery
diarrhea, hypokalemia, hypochlorhydria and acidosis syndrome” (WDHHA syndrome). These tumor caused by
to non-insulin-secreting pancreatic islet tumor that associated with elevated vasoactive intestinal
polypeptide (VIP) plasma level. VIP is a potent stimulator of gut cyclic adenosine monophosphate (cAMP)
production, which leads to massive secretion of water and electrolytes mainly potassium. Over expression
of VIP causes diarrhea and cancerous growth. The other clinical features of VIPomas such as
hypercalcemia, abdominal discomfort, tetany, facial flushing are associated with the actions of VIP, which
stimulate intestinal secretion, inhibit gastric acid secretion. VIP also regulates the synthesis, secretion,
and action of neuroendocrine hormones such as secretin, glucagon, prostaglandin E, somatostatin and
pentagastrin as well as cytokines and chemokines. Diagnosis is based on clinical, laboratory test show
elevation VIP level, electrolyte and acid base imbalance also imaging such as CT scan or magnetic
resonance imaging (MRI) which shows primary tumor in the pancreas and metastasis especially in
the liver. Somatostatin receptor scintigraphy may be useful in identifying extrapancreatic VIPomas, i.e.
the sympathetic chain, colon, bronchus and occult or distant metastases. Initial treatment is to correct
volume, electrolyte, and acid-base abnormalities with intravenous normal saline, potassium chloride,
and, sodium bicarbonate. Somatostatin or long acting ocreotide is effective in reducing serum VIP levels
and promptly controlling diarrhea. Interferon alpha and glucocorticoid may be useful for reducing
symptoms. Surgical resection depends on staging of pancreatic tumor.
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be WDHHA; watery diarrhea, hypokalemia, hypo-
chlorhydria, and acidosis caused by bicarbonate
wasting.1 Other symptoms include abdominal pain,
flushing, muscle weakness, weight loss that often can
be mistaken for carcinoid syndrome.1 Several reported
series confirmed the association between certain
pancreatic tumors and watery diarrhea syndrome.2,3,4
In 1970, Said and Mutt extracted the putative hormone
causing WDHA from pig gut tissue.2,5 Finally, in 1973,
Bloom reported six watery diarrhea patients due to
pancreatic tumors were associated with elevated
plasma level these putative hormone. These extirpated
tumors were found containing large amounts of
Vasoactive intestinal polypeptide (VIP).2
EPIDEMIOLOGY
VIPomas occur with a frequency of 1 per 10,000,000
per year. The incidence of new cases of VIPomas is
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0.05-0.5 per million people per year. VIPomas arise
from the pancreas in 90% of cases, but they may also
be found in periganglionic tissue or other sites
including the colon, bronchus, adrenal glands, and liver.2,3
These tumors are almost always solitary, with only less
than 5% of cases being multi-centric. These tumors
are usually greater than three cm at the time of
diagnosis and are mostly found in the body and tail of
the pancreas.1,2 Approximately 60-80% of VIPomas
are malignant and have metastasized at the time of
diagnosis. Metastasis occurs most frequently in the liver
but may also occur in the lymph nodes, lung, or
kidneys. Approximately 5% of VIPomas are associ-
ated with multiple endocrine neoplasia type 1 (MEN
1) syndrome. Conversely, 17% of patients with MEN
1 develop VIPomas at some stage of their disease.
Approximately 10% of neuroendocrine tumors in
the gastrointestinal tract (except carcinoids) are
VIPomas. There have been 18 other case reports of
elevated plasma levels of VIP that have been
associated with neurogenic tumors, including
ganglioneuroblastoma, ganglioneuromas, neurofibroma,
and pheochromo-cytoma.1,3,6 In adults these tumor
present between ages 30 and 50 years. Peak incidence
occurs in the fifth decade of life, but VIPomas may
occur in all ages including young children and elderly
persons. The male-to-female ratio is approximately
1 : 1. Morbidity and mortality on WDHA syndrome is
related to long-standing dehydration with electrolyte
and severe acid-base disturbances that may cause
chronic renal failure2.
PATHOPHYSIOLOGY
VIP has 3,381 molecular weight that consists of
28 amino acids, and belongs to the secretin-glucagon
family. The VIP gene is located on chromosome 6.
VIP is normally expressed in the central nervous
system and in the neurons of the gastrointestinal,
respiratory, and urogenital tracts, where it functions as
a neurotransmitter. VIP regulates the synthesis,
secretion, and action of neuroendocrine hormones as
well as cytokines and chemokines.
Over expression of VIP causes diarrhea and
promotes cancerous growth. In the gastrointestinal tract
VIP is largely responsible for the relaxation of
vascular, smooth muscleVIP is a potent stimulator of
gut cyclic adenosine monophosphate (cAMP)
production, which leads to massive secretion of water
and electrolytes (mainly potassium).2 VIP resembles
secretin, which stimulates secretion of alkaline
pancreatic juices. In the stomach, VIP inhibits
histamine and pentagastrin-stimulated acid secretion.
VIP stimulates lipolysis and glycogenolysis and has an
inotropic effect on the myocardium. It also has




The dominant symptom of VIPoma is profused
cholera-like diarrhea that may persist 3-4 years before
the diagnosis established. Diarrhea may be episodic
initially but becomes continuous as the tumor
progresses. Stool volumes were greater than 3 liters
per 24 hour in 70% of cases, and may exceed 6-8
liters per 24 hours. The stool is typically odorless,
tea-colored, without blood or mucus. Stools have large
amount potassium, and bicarbonate (average potassium
300 mmol/24 hours). These condition cause
hypokalemia and metabolic acidosis. Hypokalemia may
present as muscle cramps and weakness.1,2,3
The diarrhea is always secretory and will not
disappear with fasting for 48 hours. This symptom may
be confused with the diarrhea found in the Zollinger-
Ellison syndrome. Loss of water, sodium, and
chloride may lead to volume depletion, dehydration, and
exhaustion in patients unable to replace fluid and
electrolyte losses.2,3 Weight loss and even renal
failure have been reported in some patients.
The clinical features of VIPomas are associated
with the actions of VIP, which stimulate intestinal
secretion and glycogenolisis, inhibit of gastric acid
secretion, cause hypercalcemia and also cause
relaxation of the gallbladder.8-12 The structural
homology between VIP and secretin-glucagon family
like secretin, glucagon, gastric inhibitory polypeptide
(GIP), peptide histidine and isoleucin may enhance
secretion of pancreatic juice and inhibit of gastric acid
secretion that cause hypochlorhydria/achlorhydria.7,11
Hypercalcemia  has been noted in nearly 50% of
patients and it may relate to dehydration, electrolyte
disturbances secondary to diarrhea, coincidental
multiple endocrine neoplasia (MEN) accompanied by
hyperparathyroidism, and secretion by the tumor of
a calcitrophic peptide. Tetany has been reported in
several patients and may result from hypomagnesemia
secondary to the diarrhea. Nearly 8% of patients
demonstrate facial flushing (patchy erythematous) and
sometimes urticaria, that attributed to vasodilatory
effect. Abdominal discomfort or bloating has also been
reported.1,3 
Physical Examination
Volume depletion may lead to tachycardia,
decreased skin turgor, and weight loss. Patients may
present with a mildly distended abdomen.
Hepatomegaly may be detected if liver metastasis has
occurred. 
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Biochemical
VIP levels in VIPoma patients are markedly
elevated, to levels 160-250 pmol/L or higher during
severe diarrhea. Normal VIP plasma level is only
20-30 pmol/L or less (determined by radio-
immuno assay). VIP levels should be drawn after
fasting. Because VIP is degraded rapidly, a protease
inhibitor such as aprotinin is added to the blood sample
that should be kept frozen at -70°C until processed.1
VIP is synthesized as the 170 amino acid precursor
pre-pro VIP, which post translationally modified to
yield the 28 amino acid VIP as well as peptide
histidine and methionine (PHM) and other fragments.13
False-positive elevations of VIP can be observed in
patients with small bowel ischemia or severe low-flow
states caused by diarrhea and secondary dehydration
not associated with VIP-producing tumors.14-16
VIP is not the only agent implicated in the diarrhea
syndrome. Gastrin, secretin, glucagon, enteroglucagon,
GIP, PP, VIP, thyrocalcitonin (TCT), prostaglandins
E, somatostatin, neurokinin, and peptide fragments of
pre-pro VIP or any one of a number of combinations
have been implicated as possible etiologic agents of
the diarrhea syndrome.16 Between periods of watery
diarrhea, the VIPoma, unlike many endocrine tumors
of the gut (e.g. insulinoma, gastrinoma), may not be
actively secreting VIP. If VIP level is elevated when
diarrhea still persists after fasting, a VIPoma should
be strongly suspected.
Imaging
Imaging studies are primarily focused on
the pancreas because 90% of VIPoma tumors are
located in the pancreas. CT scan will successfully
identify the primary tumor and metastasis especially
in the liver. Peng et al reported that all VIPomas of
the pancreatic body and tail were identified on CT,
but only 71% of VIPomas in the pancreatic head were
successfully identified. Magnetic resonance imaging
(MRI) may be used if a CT scan is contra-
indicated. VIPomas are observed best on T1-weighted,
fat-suppressed images as low-signal intensity masses.
Liver metastases may demonstrate intensive
peripheral ring enhancement on immediate post-
gadolinium spoiled gradient-echo images. 
Somatostatin receptor scintigraphy may be useful
in identifying extrapancreatic VIPomas, particularly
those in the sympathetic chain, or metastases.2,3
Somatostatin receptor scintigraphy may be useful to
characterize an abnormality found on CT scan or to
identify occult or distant metastatic disease. It may also
be used if postsurgical changes diminish the clarity of
a CT scan images. Sensitivity for localization of all
pancreatic endocrine tumors has been reported at
80-90%, with 92% sensitivity for tumors larger than
one cm. Octreotide scanning may be useful, especially
if metastases are being sought, but may not be quite as
helpful in small primary lesions.2 Single-photon
emission CT, as suggested by recent investigations.
Some reports demonstrate successful VIPoma
localization with technetium 99 m sestamibi.
Transabdominal ultrasonography (USG) may be used
for early screening to exclude liver metastases, which
may be present as hepatic calcifications.
Other Test
Hypochlorhydria or achlorhydria is seen in at least
75% patients. This can be determined by measuring
gastric pH or basal gastric acid out. Typical stool
volumes are more than 3 liters per day if less than
700 ml diagnosis might exclude.
Procedure
Endoscopic retrograde cholangiopancreatography
(ERCP) may demonstrate occlusion of the major
pancreatic duct. It also may demonstrate calcifications
in the body of the pancreas. Colonoscopy may useful
to evaluate for a possible villous adenoma as an
alternative cause of potassium-losing diarrhea.
Histologic
These tumors, like other pancreatic endocrine
tumors, are felt to arise from the pluripotent cells in
ductal epithelium. Histologic examination usually
reveals sheets of nested, uniform-appearing cells with
round nuclei and low mitotic rate, typical for neuro-
endocrine tumors. Immunohistochemistry staining is
positive for VIP and chromogranin A. Under electron
microscopy, neurosecretory granules may be seen
clustering around Golgi complexes and the
endoplastic reticulum. Classifying a tumor as




Initial treatment is aimed to correct volume,
electrolyte, and acid-base abnormalities with
intravenous normal saline, potassium chloride, and,
sodium bicarbonate. A trial of prostaglandin synthesis
inhibitors (e.g. indomethacin), phenothiazines, and
lithium may be warranted.18 Somatostatin is highly
effective in reducing serum VIP levels and promptly
controlling diarrhea in more than 90% of patients.
Octreotide is delivered subcutaneously at an initial dose
of 50-100 mcg 3 times a day, which may be titrated up
for symptom control to a maximum of 500 mcg 3 times
a day. A long-acting formulation of octreotide called
Sandostatin LAR allows for once monthly intragluteal
administration which starting dose is 10-20 mg per
month. The dose can subsequently be titrated up to
a maximum of 40 mg monthly. Diarrhea recurs when
treatment is discontinued. It is currently debated
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whether somatostatin analogues also diminish tumor
size. Long-term octreotide treatment frequently results
in gradual resistance to this treatment. When maximum
tolerable doses of octreotide are unable to control
symptoms, interferon alpha may be added to control
diarrhea, with possible modest reduction in tumor
size. Glucocorticoids are less effective but less
expensive, reducing symptoms in approximately 50%
of patients.
Preoperative treatment with a proton pump
inhibitor is advisable to prevent rebound gastric acid
hypersecretion after surgical removal of tumor.
Systemic chemotherapy may be needed in cases of
unresectable or progressive disease. Streptozocin,
doxorubicin, fluorouracil, or their combination appears
to be beneficial, although the number of treated cases
has been limited. The use of radiolabeled octreotide
to target radiation treatment to VIPoma is based on
the affinity of octreotide to the somatostatin receptors
on the VIPoma cells. In one trial, half of the patients
achieved stabilization of previously progressive
tumors, with minimal bone marrow toxicity. This
therapeutic approach is still considered experimental.
Surgical Care
All operable patients with apparently resectable
disease should receive abdominal exploration with
careful staging. Intraoperative USG of the pancreas
may aid in locating an unidentified tumor. For patients
without nodal or distant metastasis, complete surgical
resection offers the only chance for a cure.1,2,3,19
Pancreatoduodenectomy is indicated when the tumor
is in the pancreatic head or processus uncinatus.
If tumor is not found at surgery, a distal
pancreatectomy may be performed. In most cases,
metastatic disease is found at the time of diagnosis. For
these patients, tumor debulking may reduce clinical
symptoms, but surgical plans ought to include
resection of more than 90% of tumor volume for
substantial clinical benefit. Postoperative octreotide
therapy will usually be needed indefinitely to control
symptoms of VIP hypersecretion from residual tumor.
Unresectable liver metastases may be treated with
hepatic artery embolization or transcatheter
chemoembolization with doxorubicin or cisplatin if
embolization is not success or not feasible for liver
metastases, percutaneous or intraoperative
radiofrequency ablation (RFA) may be attempted to
small tumor. All patients having surgery should
undergo a cholecystectomy to alleviate concerns of
gallstones with somatostatin analogue therapy in case
such therapy may be needed in the future. Orthotopic
liver transplantation has been performed in a small
number of select patients with pancreatic endocrine
tumors with approximately a 50% survival rate at five
years.
CONCLUSION
VIPomas are extremely rare tumors that cause
the “WDHHA syndrome”: watery (secretory) diarrhea,
hypokalemia, and hypohlorhydria and acidosis
(because bicarbonate wasting). These tumor were
caused by to non-insulin-secreting pancreatic islet
tumor and associated with elevated plasma level
vasoactive intestinal polypeptide (VIP). Morbidity and
mortality on WDHA syndrome is related to long-
standing dehydration with electrolyte and severe
acid-base disturbances, that may cause chronic renal
failure. The other clinical features of VIPoma such
hypercalcemia, abdominal discomfort, tetany, facial
flushing are related to secretion and action of VIP and
other neuroendocrine hormone such as secretin,
glucagon, prostaglandin E, somatostatin, etc. CT scan
or MRI will identify the primary tumor in
the pancreas and metastasis especially in the liver.
Somatostatin receptor scintigraphy may be useful in
identifying extrapancreatic VIPomas, i.e
the sympathetic chain, occult or distant metastases.
Initial treatment is to correct volume, electrolyte,
and acid-base abnormalities with intravenous
normal saline, potassium chloride, and, sodium
Table 1. Differentiation of gastrinoma and WDHHA syndrome.3 
Feature Gastrinoma WDHHA 
Diarrhea Acid Alkaline (HCO3 loss) 
Gastric acid Increased Decreased 
Gastric volume Increased Normal or decreased 
Nasogastric suction Diarrhea improves Diarrhea unchanged 
Motility Increased* Increased slightly† 
Abdominal pain Marked Rare (initially) 
Stool K+ loss Slight Marked 
Metabolic acidosis  No (alkalosis with Yes HCO3 loss, gastric suction) 
Lesion location Primary pancreas Primary pancreas, 
ganglioneuroblastoma also liver, 
wall of stomach, and duodenum 
Mediator Gastrin VIP/other 
*Motility enhanced secondary to gastric acid stimulation  
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bicarbonate. Somatostatin or long acting ocreotide is
highly effective in reducing serum VIP levels and
promptly controlling diarrhea. Interferon alpha and
glucocorticoid may be useful for reducing symptoms.
Surgical resection of pancreas tumor is based on
staging.
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